FN-1501

Uveitis, inflammation of the uveal tissues, has diverse aetiologies and contributes significantly to visual impairment. Historical descriptions from ancient civilisations through to modern times reflect evolving understanding and treatment, with advancements in immunology, diagnostics, and imaging technology. The twentieth century saw the introduction of corticosteroids and immunomodulatory agents, while the twenty-first century has seen biologics and precision medicine revolutionize treatment. Collaborative efforts and early intervention remain crucial for managing uveitis.

Chinese scientists achieved 184 days of organ function in a macaque with a gene-edited pig kidney transplant, using an improved immunosuppressive regimen. This milestone positions China competitively in xenotransplantation research, aiming for human trials.

Exploratory study (ChiCTR2000035740) enrolled patients with haematologic malignancies and SR-aGVHD from 7 Chinese centres. Patients were randomized 1:1 into MSC or control groups. Inclusion criteria: age 13-70, first allogeneic haematopoietic stem cell transplantation, SR-aGVHD grade II+, treatable within 3 days, written informed consent. Exclusion criteria: life-threatening complications, active malignant solid tumours, severe allergies, mental/neurological disorders. MSC group received hUC-MSCs PLEB001, control group received placebo. Primary endpoint: ORR at d28. Secondary endpoints: ORR at d56, DCR rate, CR rate at d28/d56, OS. Safety endpoints: AEs, SAEs, infusion toxicity. Statistical analysis: R, SAS, SPSS. Post-hoc analyses: ORR, DCR, CR rate, OS, FFS, cumulative incidence of cGVHD.

EMA's CHMP recommended 8 new medicines for approval, including Augtyro, Gohibic, and Lazcluze, and 4 biosimilars. Extensions of indication were recommended for 11 existing medicines, while marketing authorisations were refused for Cinainu and Kizfizo. CHMP also recommended Leqembi for Alzheimer's patients with specific genetic profiles and updated safety advice for Mysimba. Applications for Izelvay and Inaqovi were withdrawn.

Tacrolimus and cyclosporine A are similarly effective in maintaining long-term survival and reducing relapse in AML patients post transplant, with tacrolimus showing a lower incidence of severe grade 3-4 acute GVHD in haploidentical HCT.

First three islet transplant recipients treated with tegoprubart achieved insulin independence, with improved graft function and higher islet engraftment compared to standard care. Treatment was well-tolerated, and data will be presented at a medical summit.

ASN Kidney Week 2024 will present results from high-impact phase 3 trials on finerenone, personalized AKI recommendations, semaglutide, tacrolimus vs. mycophenolate mofetil, empagliflozin, and HSK21542 for CKD-associated pruritus, highlighting kidney protective effects, efficacy, and safety of these treatments.

A randomized, double-blind, phase III clinical trial (Aug 2019–Oct 2021) in Iran compared Xacrel (300 mg, then 600 mg every 24 weeks) to Ocrevus (same regimen) in MS patients. Primary outcome was ARR reduction equivalence at week 48. Secondary outcomes included disability progression, relapse-free patients, MRI lesion changes, and safety assessments. The study adhered to ethical and regulatory standards.

The FDA approved Niktimvo (axatilimab) for chronic graft-versus-host disease (GVHD) in patients who have progressed on at least 2 prior systemic therapies. GVHD can be acute or chronic, with chronic affecting more organs and requiring longer-term treatment. Current prevention measures, including calcineurin inhibitors and methotrexate, have reduced chronic GVHD incidence to around 30-35%, with new developments like the Orca-T platform potentially lowering it further to 5-10%. However, complete elimination of GVHD is unrealistic, necessitating ongoing treatment options.